Physician profile
David Doo
NPI 1386087559
$8,741.70
in general payments reported to CMS, 2019-2025
18 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,619 · 2020: $1,300 · 2021: $673 · 2022: $53.88 · 2023: $468 · 2024: $452 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $5,605.17 | 2019 | |
| Glaxosmithkline, LLC. | $1,950.00 | 2020-2021 | |
| Medtronic, INC. | $417.12 | 2023-2024 | Truclear, Signia |
| Intuitive Surgical, INC. | $302.09 | 2023-2025 | Da Vinci Surgical System |
| Rigel Pharmaceuticals, INC. | $76.23 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Merck Sharp & Dohme LLC | $70.50 | 2023-2025 | Keytruda, Welireg |
| Abbvie INC. | $45.87 | 2023-2025 | Venclexta |
| Genzyme Corporation | $37.53 | 2022 | |
| Jazz Pharmaceuticals INC. | $34.96 | 2022-2025 | |
| Eisai INC. | $29.18 | 2024 | |
| Adc Therapeutics America, INC. | $25.85 | 2025 | |
| Emd Serono, INC. | $25.03 | 2023 | Bavencio |
| Mirati Therapeutics, INC. | $24.83 | 2024 | Krazati |
| Astrazeneca Pharmaceuticals Lp | $23.25 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.12 | 2024 | Fruzaqla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.64 | 2025 | Libtayo |
| Stemline Therapeutics INC. | $18.41 | 2023 | Orserdu |
| Genentech USA, INC. | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Doo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.